drugset / Trial / NCT06361940
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Timeline
- Start
- 2024-09-30
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Tamoxifen | Small molecule | — | — |